Bronchiolitis, Cough, Wheezing
Conditions
Keywords
Bronchiolitis, Postbronchiolitis wheezing, Montelukast
Brief summary
The aim of the current study is to evaluate the effect of Montelukast in treatment of acute bronchiolitis and postbronchiolitis viral induced wheezing of infants 3 to 12 months of age in Bandar Abbas Children' hospital.
Detailed description
All the patients will be evaluated at the baseline, during hospitalization (daily) and at 2 months and 6 months after starting the intervention.
Interventions
DRUGMontelukast
Montelukast 4mg daily for 2 months
Sponsors
Hormozgan University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Months to 12 Months
Healthy volunteers
No
Inclusion criteria
* infant in 3-12 months of age with first episode of wheezing or bronchiolitis * written informed consent by parents
Exclusion criteria
* Previous wheezing episode or confirmed asthma or bronchiolitis * recent bronchodilator use * immune deficient * immunosuppressive drug use * croup or pneumonia diagnosis * loss of follow up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory Distress Severity Score (RDSS) | participants will be followed for the duration of hospital stay, an expected average of 3 days | RDSS is measured by wheezing (0, 1, 2)+ Cough (0, 1, 2)+Retraction (0, 1,2)+Respiratory rate(0,1,2)+ Oxygen saturation(0,1,2) scores |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| average number of cough daily= as expressed parents during visits | 6 months | none= No cough, Mild=less than 10 daily, Severe=More than 10 daily |
| Wheezing severity in the physical examination by physician | 6 Months | None= no wheezing, Mild= mild expiratory, Severe= inspiratory and expiratory |
Countries
Iran
Outcome results
None listed